Immunotherapy as treatment for Alzheimer's disease - PubMed (original) (raw)

Review

Immunotherapy as treatment for Alzheimer's disease

Cheryl A Hawkes et al. Expert Rev Neurother. 2007 Nov.

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized pathologically by the deposition of beta-amyloid (A beta)-containing extracellular neuritic plaques, intracellular neurofibrillary tangles and neuronal loss. Much evidence supports the hypothesis that A beta peptide aggregation contributes to AD pathogenesis, however, currently approved therapeutic treatments do nothing to stop or reverse A beta deposition. The success of active and passive anti-A beta immunotherapies in both preventing and clearing parenchymal amyloid in transgenic mouse models led to the initiation of an active anti-A beta vaccination (AN1792) trial in human patients with mild-to-moderate AD, but was prematurely halted when 6% of inoculated patients developed aseptic meningoencephalitis. Autopsy results from the brains of four individuals treated with AN1792 revealed decreased plaque burden in select brain areas, as well as T-cell lymphocytes in three of the patients. Furthermore, antibody responders showed some improvement in memory task measures. These findings indicated that anti-A beta therapy might still be a viable option for the treatment of AD, if potentially harmful proinflammatory processes can be avoided. Over the past 6 years, this target has led to the development of novel experimental immunization strategies, including selective A beta epitope targeting, antibody and adjuvant modifications, as well as alternative routes and mechanisms of vaccine delivery, to generate anti-A beta antibodies that selectively target and remove specific A beta species without evoking autoimmunity. Results from the passive vaccination AD clinical trials that are currently underway will provide invaluable information about both the effectiveness of newly improved anti-A beta vaccines in clinical treatment, as well as the role of the A beta peptide in the pathogenesis of the disease.

PubMed Disclaimer

Cited by

Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease.
Roher AE, Esh CL, Kokjohn TA, Castaño EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo YM, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sabbagh MN. Roher AE, et al. Alzheimers Dement. 2009 Jan;5(1):18-29. doi: 10.1016/j.jalz.2008.10.004. Alzheimers Dement. 2009. PMID: 19118806 Free PMC article.
A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques.
Hoogerhout P, Kamphuis W, Brugghe HF, Sluijs JA, Timmermans HA, Westdijk J, Zomer G, Boog CJ, Hol EM, van den Dobbelsteen GP. Hoogerhout P, et al. PLoS One. 2011 Apr 19;6(4):e19110. doi: 10.1371/journal.pone.0019110. PLoS One. 2011. PMID: 21526148 Free PMC article.
Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer's disease mouse models.
Raymond SB, Treat LH, Dewey JD, McDannold NJ, Hynynen K, Bacskai BJ. Raymond SB, et al. PLoS One. 2008 May 14;3(5):e2175. doi: 10.1371/journal.pone.0002175. PLoS One. 2008. PMID: 18478109 Free PMC article.
Identification of matrix metalloproteinase-12 as a candidate molecule for prevention and treatment of cardiometabolic disease.
Amor M, Moreno Viedma V, Sarabi A, Grün NG, Itariu B, Leitner L, Steiner I, Bilban M, Kodama K, Butte AJ, Staffler G, Zeyda M, Stulnig TM. Amor M, et al. Mol Med. 2016 Oct;22:487-496. doi: 10.2119/molmed.2016.00068. Epub 2016 Jun 30. Mol Med. 2016. PMID: 27385318 Free PMC article.
Alzheimer's disease: a healthcare burden of epidemic proportion.
Dharmarajan TS, Gunturu SG. Dharmarajan TS, et al. Am Health Drug Benefits. 2009 Jan;2(1):39-47. Am Health Drug Benefits. 2009. PMID: 25126271 Free PMC article.

Immunotherapy as treatment for Alzheimer's disease - PubMed (original) (raw)